IBD Crash Course: Foundations Intensive

When a trainee asks why we still have no curative therapy, remind them that Crohn’s original 14 patients (1932) failed what was then the best treatment — surgical resection — with a 60% recurrence rate. We have made enormous progress, but IBD remains a disease of lifelong management, not cure.

The fastest-rising incidence is now in industrializing Asia and the Middle East — Saudi Arabia’s pediatric incidence is rising 5% annually. Training capacity and drug-access planning must get ahead of this curve, not chase it.

Saudi IBD is not just Western IBD in a different passport. Younger age at onset, higher rates of consanguinity-related monogenic disease, different smoking patterns, and Hijra calendar fasting rhythms all affect how we diagnose, treat, and follow our patients.

Ask every Saudi patient about breastfeeding duration, early-life antibiotic use, and urban-vs-rural upbringing. These risk factors help frame prognosis discussions and prevention advice for their siblings and children.

Every IBD therapy ultimately succeeds or fails at the barrier — a drug that calms systemic inflammation but fails to restore epithelial integrity will not produce durable remission.

NOD2 variants (p.R702W, p.G908R, p.L1007fs) triple the risk of ileal, fibrostenotic Crohn’s disease — but NOD2 explains only ~1–2% of overall heritability. IBD is polygenic, not Mendelian.

The Th17/Treg imbalance is not a downstream consequence — it is the mechanistic core of IBD. IL-23 blockers and JAK inhibitors work because they rebalance this axis directly.

Memorize the three-target heuristic: TNF (broad), IL-23 (Th17-selective), and α4β7 (gut-selective). Every biologic decision starts by picking which of these three to deploy first.

Before you reach for a diet sheet, remember: no single dietary pattern reliably induces remission in adults. The Crohn’s Disease Exclusion Diet (pediatric data) and Mediterranean diet have the best evidence but still as adjuncts, not replacements for medical therapy.

Remission is NOT cure. Memory T cells persist in the lamina propria for years — which is why discontinuing therapy (even after deep remission) carries a 40–50% relapse rate within 12 months.

In any Saudi pediatric patient with IBD onset before age 6, monogenic testing should be considered — IL10R and XIAP mutations are actionable (HSCT is curative).

Smoking cessation is the single most impactful lifestyle intervention in CD — quitting reduces relapse risk by >40% and approaches the effect size of a biologic. Make it a prescription, not a suggestion.

Probiotics are not one-size-fits-all. VSL#3/Visbiome has data in pouchitis prevention; all other probiotic claims in IBD are unsubstantiated. Saying "try a probiotic" without specifying strain and indication is clinical malpractice.

If a patient has ileal fibrostenotic Crohn’s with a family history, think NOD2 + ATG16L1 phenotype — this subgroup tends to require early biologic therapy and benefits from proactive imaging.

When choosing first biologic, draw the cytokine cascade on paper and match the drug to the dominant driver. Fibrostenotic CD with high CRP + fecal calprotectin → think TNF or IL-23. Extraintestinal manifestations → favor systemic over gut-selective therapy.

When explaining IBD to patients, use the "forest fire" analogy: genetics is the dry wood, environment the spark, microbiome the fuel, and immunity the wind. Therapy can reduce fuel and slow wind — but we cannot yet make the wood wet.

Always record UC Montreal at worst-ever documentation — if a patient was E3/S3 two years ago but is currently E1/S0 in remission, they remain classified as E3 for surveillance and therapeutic decisions.

Upper GI endoscopy should be performed in ALL newly diagnosed Crohn’s patients — L4 disease is found in 5–15%, alters classification, and often requires PPI adjunctive therapy.

In any child under 17 with IBD, measure and plot height/weight z-scores at every visit. Growth failure often precedes GI symptoms in Crohn’s, and is itself an indication for escalation of therapy.

Write the Montreal/Paris classification at the top of your admission note and update it at every hospitalization and every colonoscopy. Classification drift is the leading cause of undertreatment.

UCEIS of 0–1 is the emerging "deep remission" endoscopic target in UC. A Mayo 0 without biopsy confirmation still has a measurable 1-year relapse risk — consider adding histologic scoring in trial settings.

For CD follow-up colonoscopy after treatment initiation, SES-CD is the single most important metric to document — insurance appeals, biologic continuation decisions, and clinical trial eligibility all depend on it.

Every post-op CD patient should have an endoscopy at 6–12 months. Do not wait for symptoms — by the time they present clinically, the damage is done.

Never perform a capsule endoscopy in known CD without a patency capsule first. Retained capsules cause obstructions that can require surgery — this is an easily preventable complication.

Ask your radiologist to explicitly comment on mural stratification and T2 signal intensity — these distinguish active inflammation (treat medically) from fibrotic stricture (consider endoscopic or surgical).

In the ED with an acutely ill CD patient, CTE is faster and better at detecting abscesses and perforations — do not delay diagnosis waiting for MRE. Save MRE for outpatient monitoring.

Every IBD center should develop IUS capability. Two key windows — ileum and sigmoid — cover most IBD and can be learned in weeks. Bedside confirmation of flare vs functional symptoms saves unnecessary admissions.

Request structured reports from your radiologists. A narrative report that says "findings suggestive of active disease" is useless — demand specific wall thickness, stricture length, and T2 characteristics.

A patient who needs a second steroid course in a year has active disease, not just flares — escalate to steroid-sparing therapy. Steroid dependence is a quality metric — audit your practice.

Never start a thiopurine without TPMT and NUDT15 genotyping — genetic testing is now cheaper than a single hospitalization for myelosuppression. Saudi populations have distinct NUDT15 variant frequencies.

Always screen for latent TB (IGRA) and HBV/HCV BEFORE any biologic. This is not optional — missed TB in Saudi Arabia carries a higher prior probability than in North America and can be fatal.

For a patient with prior lymphoma, solid organ transplant, or recurrent serious infections, vedolizumab is the safest choice. For TNF-refractory Crohn’s, IL-23 selective agents (risankizumab) now outperform ustekinumab.

JAK inhibitors are the fastest-acting oral IBD therapy — unbeatable for induction in moderate-severe UC. But their black-box profile means careful patient selection: ideal for young non-smokers without CV risk factors.

Building a personalized sequencing plan requires answering three questions: (1) How severe is the disease? (2) What are the safety constraints (age, comorbidity, fertility)? (3) What is the patient’s route preference? Match to class accordingly.

Before any biologic, complete the "pre-biologic checklist": TB (IGRA), HBV/HCV serology, HIV, varicella, MMR titer, age-appropriate cancer screening, vaccination update (non-live only once on therapy).

Start VTE prophylaxis on admission for ASUC even if the patient is bleeding — hospitalized IBD is the highest VTE risk GI condition. Missing this is a sentinel event.

For fistulizing CD, target higher infliximab trough levels (10–15 μg/mL) than for luminal disease. Abscess drainage with seton placement must precede biologic therapy — otherwise seeding an abscess is inevitable.

The highest pregnancy risk in IBD is UNCONTROLLED DISEASE — not the medications. Counsel preconception to optimize disease first, then keep therapy through pregnancy. Active disease doubles the risk of low birth weight and prematurity.

Every post-op CD patient deserves a 6–12 month colonoscopy — asymptomatic i3/i4 recurrence has the same prognostic weight as symptomatic flare. Missing this opportunity costs surgical redo rates.

Before declaring anti-TNF "failure" measure the drug level. Most "primary non-responders" are actually pharmacokinetic failures — inadequate drug exposure, not mechanism failure. Dose intensification often rescues them.

Vedolizumab is the biologic of choice for elderly-onset IBD. Safety margin over anti-TNF is meaningful, and the slower onset matters less when competing risks are long-term.

Axial spondyloarthropathy does not respond to vedolizumab because α4β7 blockade is gut-selective. In a patient with both IBD and ankylosing spondylitis, choose an anti-TNF (infliximab or adalimumab) for dual control.

Paneth cell metaplasia in the distal colon is a sign of chronic injury — normal distal colon has NO Paneth cells. This single finding raises suspicion of chronic IBD.

Granulomas are found in only 30–40% of Crohn’s biopsies, but their presence strongly favors CD over UC. Always request multiple levels of biopsy tissue — granulomas may be missed on single sections.

IBD-U (unclassified) is not a diagnosis of failure — 5–15% of cases genuinely cannot be classified. Forcing a premature UC or CD label can harm patients if subsequent behavior contradicts it.

Every dysplasia diagnosis must be confirmed by a second expert GI pathologist before colectomy. Inter-observer variability for LGD is 30%+ — second opinion can save a colon.

A baseline score below 60% is not a failure — it is a starting point. Every fellow’s gaps are unique, and the monthly modules are designed around that reality.

Self-rating above faculty-rating is common in fellows (the Dunning-Kruger effect). Embrace the discrepancy as learning data, not personal failure — identifying blind spots is what fellowship is for.

Allocate 1 hour per week to reviewing and updating your learning plan. Gaps that are named and scheduled are 5× more likely to be closed than vague intentions.

The best IBD specialists are made, not born. Write down who you want to be in 5 years, then reverse-engineer the steps. Your ILP is the first step of that plan.